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Abstract MAT1 (me¤nage a' trois1) functions as an assembly/
targeting factor of CAK (cyclin-dependent kinase-activating
kinase). In a search for MAT1-interacting proteins using yeast
two-hybrid system, MCM7 (minichromosome maintenance 7), a
member of a family of DNA licensing factors, was identified. The
physical interaction between MAT1 and MCM7 was confirmed
in vivo in yeast cells and verified with in vitro protein binding
assays. Further studies showed the RING-finger motif of MAT1
is not required for the interaction with MCM7, while the C-
terminal domain of MAT1 is indispensable. Immunoprecipitation
of MCM7 in human osteosarcoma MG63 cells demonstrated
that MCM7 associates with the CAK complex in vivo. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
MAT1 (me¤nage a' trois1) was initially identi¢ed as the third
subunit of the cyclin-dependent kinase (CDK)-activating ki-
nase (CAK), the other two subunits being the catalytic sub-
unit CDK7 and the regulatory subunit cyclin H [1^3]. The
structure of MAT1 includes an N-terminal RING-¢nger motif
[1,3,4], a central coiled-coil region [4,5] and a C-terminal cy-
clin-like box [6]. MAT1 functions as an assembly factor to
promote the stability and activation of the CDK7^cyclin H
complex [1,3,4]. Each of these structural domains may func-
tion to mediate distinct protein^protein interactions [1,3,7,8].
However, the RING-¢nger motif of MAT1 is not required for
this ternary complex formation [1,3], suggesting that it may
mediate interactions with other cellular proteins. In the ab-
sence of MAT1, the interaction between CDK7 and cyclin H
and the activation of the CDK7^cyclin H complex appear to
be dependent upon the phosphorylation of a conserved site
(Thr170 in the T-loop of human CDK7) [4]. However, the
MAT1-mediated stabilization and activation of the CDK7^
cyclin H complex is independent on the phosphorylation state
of Thr170 [3,4] indicating that MAT1 functions as an activat-
ing assembly factor which is able to bypass the requirement
for T-loop phosphorylation in the enzymatic activation of
CAK.
In addition to its function as an assembly factor, MAT1
also serves as a targeting subunit of CAK to determine its
substrate speci¢city [9,10]. Two major classes of putative
CAK substrates have been identi¢ed [11] : (i) the CDK sub-
family including CDC2 [12], CDK2 [12], CDK3 [13], CDK4
[14] and CDK6 [15] ; and (ii) components of the transcrip-
tional machinery including carboxyl-terminal domain (CTD)
of the large subunit of RNA polymerase II [16], TFIIE [9],
TFIIF [9], TBP [10], the transcription factor Oct-1 [17], and
the tumor suppressor protein p53 [18,19]. In the presence of
MAT1, CDK7^cyclin H exhibits an increase in its ability to
phosphorylate the CTD of RNA pol II over CDK2 [9,10].
Moreover, it has been demonstrated that both p53 [18,19]
and Oct-1 [17] are phosphorylated by CDK7^cyclin H in a
MAT1-dependent manner. Therefore, in a manner similar to
the activating/targeting properties initially demonstrated for
cyclin A [6,20], MAT1 functions both as a positive regulating
subunit and a targeting subunit that ultimately determines the
substrate speci¢city of the multifunctional CAK complex.
To further understand the biochemical function(s) of
MAT1, we performed a yeast two-hybrid screen to identify
additional human cDNAs encoding MAT1-interacting pro-
teins. Here, we report that one of the cDNAs isolated from
this screen encodes human MCM7 (minichromosome mainte-
nance 7), a new member of a growing family of DNA licens-
ing factors known to be involved in the regulation of DNA
replication. Further studies con¢rmed the protein^protein in-
teraction between MAT1 and MCM7 in vitro and in vivo,
suggesting an additional function of the CDK7^cyclin H^
MAT1 kinase complex.
2. Materials and methods
2.1. Cell line, cell culture, and antibodies
Human MG63 osteosarcoma cells were cultured in minimum essen-
tial medium (MEM) supplemented with 10% fetal bovine serum and
antibiotics penicillin and streptomycin. Human 293T kidney epithelial
cells were cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
supplemented with 10% fetal bovine and antibiotics penicillin and
streptomycin. The polyclonal anti-cyclin H (sc-609) and anti-CDK7
(sc-529) antibodies were purchased from Santa Cruz Biotechnology.
The polyclonal anti-MCM7 antisera were generously provided by Dr.
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Masatoshi Fujita, Aichi Cancer Center, Nagoya, Japan. Polyclonal
antisera recognizing MAT1 were raised in rabbits against the puri¢ed
recombinant fusion proteins MAT1-6xHIS, which could speci¢cally
recognize recombinant and endogenous MAT1 proteins in terms of
Western blotting and immunoprecipitation (data not shown).
2.2. Two-hybrid library screening
The Matchmaker two-hybrid system was obtained from Clontech
(Clontech Laboratories, Inc., USA), and two-hybrid library screening
was carried out as described by the manufacturer [21]. Human full-
length MAT1 cDNA encoding 309 amino acids was cloned into the
vector pGBT9 as a fusion with the yeast Gal4 DNA binding domain.
The library used for screening was a HeLa cDNA library cloned at
the EcoRI-XhoI site of pGADGH as a fusion with the Gal4 activation
domain. The pGBT9-MAT1 ‘bait’ and pGADGH cDNA fusion li-
brary were co-transformed into the yeast strain HF7c using the lith-
ium acetate procedure. Co-transformants were plated onto selection
medium lacking tryptophan, leucine and histidine, and surviving
clones were further tested for L-galactosidase activity using a colony
lift ¢lter assay according to the manufacturer’s protocols. Then the
plasmid DNAs were isolated from positive yeast clones, and a PCR
strategy was utilized to amplify the cDNA insert at EcoRI-XhoI sites
within the plasmid pGADGH cDNA. The insert cDNAs were sub-
cloned into a TA cloning vector (Invitrogen), and prepared for DNA
sequencing analysis by column chromatography (QIAGEN). Based on
the results of a NCBI BLAST search, the insert DNA from clone #14
was determined to carry 489 base pairs (bp) which encodes the
C-terminal domain of MCM7 cDNA, designated MCM7c.
2.3. Two-hybrid protein^protein interaction assays
The truncated MCM7c cDNA was cloned back into pGADGH at
the EcoRI-XhoI site. In addition, a MAT1 [2] N-terminal fragment
(1^576 bp) and a MAT1 C-terminal fragment (196^930 bp) were
cloned into pGBT9. The pGADGH-MCM7c construct was co-trans-
formed into yeast strain Y190 with pGBT9-MAT1, pGBT9-MAT1(1^
576) or GBT9-MAT1(196^930), respectively. For the surviving co-
transformants, nutrition selection in the presence of 45 mM 3-amino-
triazole and a ¢lter L-gal assay were performed as described above.
2.4. Expression and puri¢cation of recombinant MAT1 protein
Full-length human MAT1 cDNA was cloned into the bacterial ex-
pression vector pET23d (Novogen) as a fusion protein with a C-ter-
minal 6xHIS tag. The recombinant MAT1 proteins were expressed in
Escherichia coli [22], then puri¢ed, renatured, and dialyzed as de-
scribed previously [23].
2.5. In vitro transcription/translation and binding assay
Total RNAs were extracted from human 293 cells (embryonic kid-
ney epithelial cells) by phase separation using Trizol (Gibco BRL).
Human full-length MCM7 cDNA was ampli¢ed by RT-PCR and
cloned into the pET23d vector (Novogen). In vitro transcription/
translations were performed using the TNT coupled reticulocyte lysate
system (Promega) with pET23d-MCM7 as a template in the presence
of [35S]methionine/cysteine (ICN), as described by the manufacturer
[24]. For evaluation of protein binding, MCM7 lysates were incubated
with puri¢ed renatured recombinant MAT1 proteins at 30‡C for 20
min, pre-immune sera or anti-MAT1 antisera were added for another
incubation at 4‡C for 1 h, and immune complexes were collected by
the addition of protein A-Sepharose. The bound proteins were eluted
with SDS bu¡er and subjected to SDS^PAGE and autoradiography.
2.6. Metabolic labeling and immunoprecipitation
Human MG63 osteosarcoma cells grown to 70% con£uence were
washed with prewarmed 1UPBS, and were preincubated with Dulbec-
co’s modi¢ed Eagle’s medium without glutamine, methionine, and
cysteine (ICN) supplemented with 10% dialyzed fetal bovine serum
(Irvine Scienti¢c) at 37‡C for 30 min. [35S]Met/Cys (1.4 mCi/180 Wl,
ICN) was added directly to the culture media to e¡ect a ¢nal concen-
tration of 100 WCi/ml, and the cell cultures were incubated at 37‡C for
4 h. The cells were lysed followed by centrifugation. The cell lysates
were further clari¢ed with protein A-Sepharose, and incubated with
either pre-immune sera (control) or speci¢c antibodies at 4‡C for 2 h.
The resulting immune complexes were collected with protein A-Seph-
arose, followed by washing with 1UPBS. The bound proteins were
eluted in SDS bu¡er, and subjected to SDS^PAGE and autoradio-
graphy.
3. Results
3.1. Identi¢cation of MCM7 as a putative MAT1-interacting
protein
To identify potential MAT1-interacting proteins, a yeast
two-hybrid library screening was employed. Out of 3.6U106
double transformants, V2000 clones showed His-independent
growth. Among these 2000 His transformants, 41 positive
clones expressed the L-galactosidase activity indicating appre-
ciable protein^protein interaction. After the isolation and se-
quencing of the insert DNAs from pGADGH cDNA in the
positive clones, the resulting DNA sequences were subjected
to a NCBI BLAST similarity search. One particular insert
DNA contained 489 bp identical to 3P-end of MCM7
cDNA, designated as MCM7c. MCM7 is a new member of
the minichromosome maintenance (MCM) family, a growing
family of DNA licensing factors involved in the initiation of
DNA replication.
3.2. Veri¢cation of the in vivo interaction between MAT1 and
MCM7 in the yeast two-hybrid system
To con¢rm the interaction between MAT1 and MCM7c in
vivo, and to identify the MAT1 domains that interact physi-
cally with MCM7c, a second yeast two-hybrid protein^protein
interaction study was carried out. MCM7c was cloned back
into pGADGH. Full-length MAT1 (1^930 bp), N-terminal
MAT1 (1^576 bp), and C-terminal MAT1 (196^930 bp)
were cloned into pGBT9. PGADGH-MCM7c was co-trans-
formed with pGBT9-MAT1, pGBT9-MAT1(1^576) and
pGBT9-MAT1(196^930), respectively, into yeast strain Y190.
Con¢rmation tests were performed to detect the false-positive
interactions: pGADGH was co-transformed with pGBT9,
pGBT9-MAT1, and pLAM5P, respectively, and pGBT9 was
co-transformed with pMCM7c. In addition, pTD1 was co-
transformed with pVA3 to serve as a positive control. These
Fig. 1. Yeast two-hybrid assay of the interaction between MAT1
and MCM7. The assay was carried out as described in detail in Sec-
tion 2. The co-transformants of pairwise constructs were subjected
to nutrition selection assay and L-galactosidase activity assay.
A: Schematic layout of co-transformed pairwise constructs.
B: Growth on the SD/-trp-Leu-His plates. C: Filter assay of L-ga-
lactosidase activity.
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tests demonstrated the original positive result and con¢rmed
the absence of false-positive interactions (Fig. 1). Speci¢cally,
L-galactosidase and nutrition selection positive clones ap-
peared in the co-transformation of pGBT9-MAT1 and
pGADGH-MCM7c (Fig. 1), indicating the speci¢c interaction
between MAT1 and MCM7c, which further con¢rmed the
result of the initial two-hybrid library screening. Moreover,
positive clones also appeared in the pGADGH-MCM7c co-
transformation with pGBT9-MAT1(196^930), but not with
pGBT9-MAT1(1^576) (Fig. 1), indicating that MCM7c inter-
acts with the C-terminal MAT1 but not N-terminal domain of
MAT1, which includes the RING-¢nger domain. In the pre-
vious report, it is found that the RING ¢nger of MAT1 is not
required for CDK7^cyclin H assembly [1,3]. Since RING-¢n-
ger motif of MAT1 is most likely to mediate protein^protein
interactions [3], we speculate that MAT1 interacts with other
proteins through this RING-¢nger motif (see Section 4). Tak-
en together, these experiments demonstrated the C-terminal
domain of MAT1 is indispensable for MAT1’s binding to
MCM7.
3.3. Veri¢cation of the physical interaction between MAT1 and
MCM7 in vitro
Although the speci¢c physical interaction between MAT1
and MCM7c was detected and con¢rmed in yeast cells, we
wished to verify the interaction between MAT1 and full-
length MCM7. To address this issue, protein binding assays
were performed with a combination of in vitro translated
(IVT) proteins and puri¢ed recombinant MAT1 proteins
(Fig. 2A). First, IVT full-length MCM7 produced in rabbit
reticulocyte extract was incubated with puri¢ed renatured re-
combinant MAT1 in the presence or absence of mammalian
cell lysate, which served as a control for interference or facil-
itation by additional soluble proteins. As shown in Fig. 2B
(lanes 1^2), MAT1 bound MCM7 as determined by immuno-
precipitation analysis, which is consistent with the results ob-
tained in yeast cells. This binding is found to be independent
of cell lysate (compare Fig. 2B, lanes 1 and 2), indicating the
direct interaction between MAT1 and MCM7, and additional
cellular factors are dispensable. Moreover, to determine the
speci¢city of this interaction, a non-related control protein
luciferase was produced by in vitro transcription/translation
and included in the protein binding assay. Both IVT luciferase
and full-length MCM7 were incubated with puri¢ed renatured
recombinant MAT1. As shown in Fig. 3 (lane 2), MAT1
bound MCM7, but not luciferase, indicating the speci¢c bind-
ing of MAT1 with MCM7.
3.4. Association of MCM7 with CAK complexes (CDK7,
cyclin H, MAT1) in mammalian cells
To determine whether MCM7 actually associates with the
CAK complex in mammalian cells, a co-immunoprecipitation
assay was performed. Human osteosarcoma MG63 cells were
metabolically labeled with [35S]methionine/cysteine, followed
by immunoprecipitation with a series of antibodies, as indi-
cated in Fig. 4. Anti-MCM7 antibodies e⁄ciently precipitated
endogenous MCM7, which migrates on SDS^PAGE at about
86 kDa (Fig. 4, lane 3). Both anti-cyclin H and anti-CDK7
antibodies co-immunoprecipitated an 86 kDa protein, pre-
cisely the expected size of endogenous MCM7 (Fig. 4, lanes
4^5), while this protein was not visible in the immunoprecipi-
tation reactions performed with non-immune sera (Fig. 4, lane
Fig. 2. MAT1 directly interacts with MCM7 in vitro. A: The puri-
¢ed renatured recombinant MAT1 proteins were subjected to SDS^
PAGE, and stained with Coomassie blue. B: In vitro
[35S]methionine-labeled MCM7 was incubated with recombinant
MAT1 in the presence (lanes 1, 4) or absence (lane 2) of cell lysate,
followed by the addition of anti-MAT1 antisera (lanes 1, 2) or pre-
immune sera (lane 4). The immune complex was precipitated with
protein A-Sepharose, and subjected to SDS^PAGE and autoradiog-
raphy. The speci¢city of anti-MAT1 antisera was assessed and
shown in the presence (lane 3) or absence (lane 5) of cell lysate.
Five percent of the MCM7 input is loaded in lane 6. Molecular
mass markers are indicated on the left.
Fig. 3. The interaction between MAT1 and MCM7 is speci¢c. In vi-
tro [35S]methionine-labeled MCM7 and luciferase were mixed and
incubated with recombinant MAT1, followed by the addition of
anti-MAT1 antisera (lane 2) or pre-immune sera (lane 3). The im-
mune complex was precipitated with protein A-Sepharose, subjected
to SDS^PAGE and autoradiography. The speci¢city of anti-MAT1
antisera was assessed and shown in lane 4. Five percent of the
MCM7 and luciferase mixture is loaded in lane 1. Molecular mass
markers are indicated on the left.
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1). In contrast to the demonstrable immunoprecipitation of
MCM7 by anti-CDK7 and anti-cyclin H antibodies, anti-
MAT1 antisera failed to precipitate MCM7 directly (Fig. 4,
lane 2) for reasons, which remain speculative. Conceivably,
the anti-MAT1 antisera either (i) disrupted the multimeric
complexes, (ii) introduced stearic hindrances which precluded
e⁄cient precipitation and identi¢cation of the multimeric
complexes, or (iii) failed to interact adequately with MAT1
which is tightly bound in CAK/MCM7 complexes. Nonethe-
less, the immunoprecipitation of metabolically labeled 86 kDa
protein with anti-CDK7 and anti-cyclin H antibodies indi-
cated that a physical interaction of MCM7 with CAK com-
plexes is observed in vivo.
4. Discussion
In this study, we identi¢ed MCM7, a DNA licensing factor
[25], as a MAT1-interacting protein using the yeast two-hy-
brid system. The direct physical interaction between these
proteins was subsequently con¢rmed in yeast cells and in a
series of in vitro assays (Figs. 1, 2B, 3). In mammalian cells in
vivo, it was further con¢rmed that MCM7, either directly or
indirectly, associates with speci¢c subunits of the CAK com-
plex, i.e. CDK7, cyclin H and MAT1, as detected by immu-
noprecipitation (Fig. 4). Furthermore, it was demonstrated
that the RING-¢nger domain of MAT1 is not required for
its association with MCM7c, while the C-terminal domain of
MAT1 is found to be indispensable for this association (Fig.
1).
In a recent study of the association of MCM proteins with
the RNA polymerase II (pol II) holoenzyme [26], it was dem-
onstrated that several MCM proteins, including MCM7, co-
purify with pol II along with general transcription factors
such as TFIIH, indicating MCM7 associates either directly
or indirectly with this transcriptional factor. TFIIH is a mul-
tisubunit complex consisting of at least nine polypeptides, and
all three subunits of CAK, including CDK7, cyclin H and
MAT1, are identi¢ed as components of the TFIIH complex
[16,27]. Therefore, the present ¢nding that MCM7 associates
directly with MAT1 in the CAK complex, is in agreement
with, and veri¢ed by the observation that MCM7 interacts
physically with TFIIH.
While the functional signi¢cance of the interaction between
MCM7 and MAT1 remains to be demonstrated, it is known
that MAT1 functions as an assembly factor [1,3,4] and as a
targeting factor of CAK [9,10,17], and that the multifunction-
al CAK has been proposed to be involved in cell cycle control,
transcriptional regulation and DNA repair [11]. As the pri-
mary targeting factor of CAK, MAT1 is able to modulate
CAK activities and functions via its physical and functional
interactions with other target proteins, such as transcription
factor Oct-1 [17]. In this case, MAT1 interacts with the POU
domain of Oct-1, which e¡ectively targets CAK to Oct-1 and
results directly in its phosphorylation. Therefore, MAT1 tar-
gets and directs CAK activity to the transcription factor Oct-
1, as well as the catalytic subunit of S-phase CDKs. Accord-
ingly, the interaction between MAT1 and MCM7 may have
implications for the allostatic regulation of MCM7, although
this remains speculative at present. Alternatively, the RING
¢nger of MAT1, and indeed many RING-¢nger proteins, are
proposed to function in the ubiquitin degradation pathway
[28,29], which may thereby regulate the metabolism of the
pol II/TFIIH complexes.
MCM7 is a relatively new member of the MCM protein
family (MCM2^7), which performs a critical role in DNA
synthesis to ensure DNA is replicated precisely once per cell
cycle [30]. The initiation of DNA replication occurs through
the association of a set of prereplicative complexes (including
the MCM family) with chromatin during G1, followed by
activation of S-phase CDKs, which trigger DNA replication
and block the assembly of new prereplicative complexes [31].
It is further suggested that the loading of MCM proteins onto
chromatin may be regulated by Cdc6p and by CDKs [32].
Moreover, there is evidence that suppression of mitotic
CDK activity by a selective CDK inhibitor leads to reloading
of MCM7 to chromatin [32]. Therefore, since CAK targets
various CDKs as its putative substrates [11], it is conceivable
that CAK regulates MCM7 function indirectly through the
activation of another associated CDK. In conclusion, the re-
sults of the present study suggest that MAT1 and CAK be
further implicated in the regulatory biology of DNA replica-
tion through their physical interaction with MCM7.
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